Skip to content
Screener

Accrued Expenses at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$13.47B-22.5%
Amgen logo
AmgenAMGN
$17.19B+14.4%
WHW
Whitehawk TherapeuticsWHWK
$9.31M+8.1%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$3.24M+1.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$21M0.0%
Immunome logo
ImmunomeIMNM
$29.72M+63.1%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.54B+76.7%
Enterprise value$3.41B+78.1%
P/S15.2×+10.5×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable$20,736$17,584
Accrued liabilities43,74540,892
Operating lease liabilities, current350339
Total current liabilities64,83158,815
Long-term operating lease liabilities28,25027,575
Total liabilities93,08186,390

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s accrued expenses?
IDEAYA Biosciences, Inc. (IDYA) reported accrued expenses of $43.75M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s accrued expenses changed year-over-year?
IDEAYA Biosciences, Inc.'s accrued expenses increased by 32.9% year-over-year, from $32.91M to $43.75M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s accrued expenses has grown at a 369.1% compound annual growth rate (CAGR), from $18K to $40.89M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about IDEAYA Biosciences, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude